BASIC AND CLINICAL STUDIES ON AC-1370

Abstract

Fundamental and clinical studies of AC-1370, a new injectable cephem, were carried out, and the following results were obtained.
1) Sensitivities of clinically isolated strains to AC-1370 were tested by agar plate dilution method and compared with those of cefazolin (CEZ), cefmetazole (CMZ) and cefoperazone (CPZ).
The MICs of AC-1370 against S. aureus were inferior to those of CEZ, CMZ and CPZ. Antimicrobial activities of AC-1370 against gram negative bacterias except Ps. aeruginosa were almost equal or inferior to those of CMZ. The MICs against Ps. aeruginosa were superior to those of CMZ but inferior to CPZ and the peak MIC value of AC-1370 was 100μg/ml.
2) The quantitative NBT reduction test of murine alveolar macrophages in vitro was accelerated in the presence of 100 μg/ml of AC-1370, but not in the same concentration of cefmenoxime (CMX).
3) The maximum serum levels after 1.0 g drip infusion of AC-1370 over a period of 1 hour was 47.0 μg/ml; 10.01.tgiml at 2 hours and 3.6 μg/ml at 4 hours from after start of infusion.
The urinary excretion rate of AC-1370 up to 6 hours was 92.1%. 4) Eleven patients with respiratory tract infections were administered with doses of 1.0 g of AC-1370 twice a day by drip infusion ranging from 4-21 days.
The clinical efficacy was good in 6, fair in 3, poor in 1, unevaluable in 1. The effective rate was 60.0%.
Eruption was observed in one patient but no abnormal laboratory findings were observed.